CYT387: Phase I/II started

Cytopia began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate oral CYT387 given once daily in 30-60 patients. In October, YM BioSciences Inc. (TSX:YM; NYSE-A:YMI, Mississauga, Ontar...